The Role of Sacubitril/Valsartan in Post-acute Myocardial Infarction

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

Sacubitril/Valsartan (SAC/VAL) is a new treatment of congestive heart failure (CHF) recently indicated as class I, level of evidence B in the recent European Society of Cardiology (ESC) guidelines 2016 of CHF. PARADIGM-HF trial demonstrated a significant improvement of morbidity and mortality with SAC/VAL in comparison to enalapril. So far, no data available about the effect of usage of SAC/VAL post-acute myocardial infarction (AMI) except in animal experimental models.

The purpose of the research is evaluation of the effects of SAC/VAL in post-AMI in comparison to the traditional Angiotensin Converting Enzyme inhibitors (ACEs inhibitors) or Angiotensin II Receptor Blockers (ARBs) in a real-life clinical trial in treatment of post-AMI patients with reduced left ventricular (LV) systolic function.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Young Investigator Group of Cardiovascular Research
• Treatments: LCZ 696; Sacubitril and valsartan sodium hydrate drug combination; Valsartan

Criteria

Inclusion Criteria:

• Post-AMI patients who underwent successful PPCI and LVEF ≤40%.

Exclusion Criteria:

• Post-AMI patients who underwent successful PPCI and LVEF >40%.

• History of hypersensitivity or allergy to any of the study drugs, as well as known or suspected contraindications to the study drugs.

• Symptomatic hypotension and/or an SBP < 100 mmHg.

• Estimated GFR < 30 mL/min/1.73m2 as measured by the simplified MDRD formula or serum potassium > 5.2 mmol/L.